Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial (RCTCogRehab)
Cognitive Impairment, Dementia, Comorbidities and Coexisting Conditions
About this trial
This is an interventional prevention trial for Cognitive Impairment focused on measuring Dementia, Comorbidity, Cognitive rehabilitation, Motor rehabilitation, Digital-based cognitive rehabilitation
Eligibility Criteria
Inclusion Criteria: Age Between 65 and 80 years. Neurocognitive Disorder due to vascular disease with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset < 12 months. Neurocognitive Disorder due to multiple etiology with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset < 12 months. Exclusion Criteria: Other known neurological conditions involving cognitive functioning (e.g. Parkinson's disease, Multiple Sclerosis, head trauma, alcohol abuse). Severe organic instability. Neoplasia in progress. Severe psychiatric condition. Illiteracy. Severe perception deficits. Severe motor disability. Specific intellectual deficit. Participation in other forms of training or neurostimulation in the previous 6 months. Pharmacological interventions of neurological pertinence in the month before the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Group 1
Group 2
Group 3
Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.